Delivery Order 36F79724D0101-36C24924F0211
Award Date 8/20/24
Potential Completion Date 8/30/24
Potential Value $311K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, for its BREYANZI chimeric antigen receptor (CAR) T cell therapy. The $310,935.67 firm fixed price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9 and has an ultimate completion date of October 31, 2024. The award is not a set-aside contract. Bristol-Myers Squibb supplies the BREYANZI treatment, which is used to treat...
- This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to the U.S. Department of Veterans Affairs (VA). The contract, valued at $310,953.57, was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on December 13, 2024. The work is primarily performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey, and the delivery order has a completion date of January 12, 2025. This award is a delivery order...
- This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy for treating non-Hodgkin lymphoma, to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on a firm fixed price basis with a potential value of $310,935.67. The contract has a completion date of June 10, 2024 and is not associated with...
- This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to patient ENR-018564. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9). The contract is a firm fixed price delivery order with a ceiling value of $310,935.67 and a performance period ending on January 5, 2025. This order is placed against...
- This is a federal delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer. The $335,042.65 firm fixed price contract is for the delivery of the BREYANZI chimeric antigen receptor (CAR) T cell therapy for transplant treatment. The contract is part of Bristol-Myers Squibb's larger $12.28 billion Federal Supply Schedule contract with the VA, which provides a wide range of drugs, pharmaceuticals, and...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Bristol-Myers Squibb Company under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy. The $310,935.67 firm-fixed price award has a period of performance through May 10, 2024, with all work to be performed in Lawrenceville, New Jersey. No set-aside designation was used...
- This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the supply of the cancer treatment drug BREYANZI. The $335,042.65 firm fixed price contract runs through March 16, 2026 and supports the VA's mission of providing advanced medical therapies to eligible veterans, particularly in the area of oncology and specialized immunotherapy treatments. The contract is issued under Bristol-Myers Squibb's...
- This is a firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer. The contract, valued at $670,085.30, is for the delivery of the emergency cancer therapy BREYANZI infusion. It is part of a larger Federal Supply Schedule (FSS) contract between the VA and Bristol-Myers Squibb, valued at $12,278,876,570.00 and running through April 2029. The FSS contract covers a range of pharmaceutical...
- The Department of Veterans Affairs Veterans Health Administration awarded a delivery order contract to Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, for the provision of ABECMA, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T immunotherapy. The $314,322.29 firm fixed price contract has a completion date of June 10, 2024 and is part of Bristol-Myers Squibb's Federal Supply Schedule contract for pharmaceuticals and drugs with the VA. This...
- This is a $338,932.84 firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer. The contract is for the supply of 1 unit of the ABECMA injection, a chimeric antigen receptor (CAR) T cell therapy used for cancer treatment. The delivery order was issued under Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the VA, which covers a broad range of pharmaceutical and...